Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics Limited has announced that its Annual General Meeting for the financial year ending 31 March 2025 will be held on 27 August 2025. This meeting is significant for stakeholders as it includes the election of Directors, with nominations due by 9 July 2025, potentially impacting the company’s strategic direction and governance.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 5,025,547
Technical Sentiment Signal: Buy
Current Market Cap: A$91.17M
Learn more about ATX stock on TipRanks’ Stock Analysis page.